释放 ATR 抑制剂的治疗潜力：癌症治疗的进展、挑战与机遇 - Suppr

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

作者信息

Reddy Tejaswini P, Yap Timothy A

机构信息

Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Clin Transl Med. 2025 Jul;15(7):e70397. doi: 10.1002/ctm2.70397.

DOI:10.1002/ctm2.70397

PMID:40673619

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12268788/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83a2/12268788/2255f990bf3a/CTM2-15-e70397-g001.jpg

相似文献

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

Clin Transl Med. 2025 Jul;15(7):e70397. doi: 10.1002/ctm2.70397.

Research progress of ATR small molecule inhibitors in cancer therapy.

Eur J Med Chem. 2025 Oct 15;296:117804. doi: 10.1016/j.ejmech.2025.117804. Epub 2025 May 24.

Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors.

Mol Divers. 2025 Jul 20. doi: 10.1007/s11030-025-11282-8.

Molecular architecture and inhibition mechanism of human ATR-ATRIP.

Sci Bull (Beijing). 2025 Jul 15;70(13):2137-2146. doi: 10.1016/j.scib.2025.05.009. Epub 2025 May 6.

Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

JCO Precis Oncol. 2022 Feb;6:e2100211. doi: 10.1200/PO.21.00211.

ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer.

Cytokine. 2025 Sep;193:156980. doi: 10.1016/j.cyto.2025.156980. Epub 2025 Jun 17.

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.

J Cancer Res Clin Oncol. 2023 Sep;149(11):8605-8617. doi: 10.1007/s00432-023-04804-0. Epub 2023 Apr 25.

A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase.

Biochem Pharmacol. 2025 Jul 12;241:117160. doi: 10.1016/j.bcp.2025.117160.

ATR-SEIRAS for Single-Atom Electrocatalysis.

Acc Chem Res. 2025 Jul 15;58(14):2282-2295. doi: 10.1021/acs.accounts.5c00303. Epub 2025 Jun 24.

Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.

本文引用的文献

Targeting ATR in patients with cancer.

Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20.

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.

Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5.

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28.

ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration.

Nat Commun. 2020 Sep 24;11(1):4828. doi: 10.1038/s41467-020-18580-9.

Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

Cancer Res. 2020 Jun 1;80(11):2094-2100. doi: 10.1158/0008-5472.CAN-19-3126. Epub 2020 Mar 3.

A decade of clinical development of PARP inhibitors in perspective.

Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192.

State-of-the-art strategies for targeting the DNA damage response in cancer.

Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z.

Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi: 10.1016/j.stem.2017.07.010. Epub 2017 Aug 10.

ATR: an essential regulator of genome integrity.

Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27. doi: 10.1038/nrm2450. Epub 2008 Jul 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

作者信息

Reddy Tejaswini P, Yap Timothy A

机构信息

Department of Internal Medicine, Baylor College of Medicine, Houston, Texas, USA.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

出版信息

Clin Transl Med. 2025 Jul;15(7):e70397. doi: 10.1002/ctm2.70397.

DOI:10.1002/ctm2.70397

PMID:40673619

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12268788/

Abstract

摘要

相似文献

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

Clin Transl Med. 2025 Jul;15(7):e70397. doi: 10.1002/ctm2.70397.

Research progress of ATR small molecule inhibitors in cancer therapy.

Eur J Med Chem. 2025 Oct 15;296:117804. doi: 10.1016/j.ejmech.2025.117804. Epub 2025 May 24.

Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors.

Mol Divers. 2025 Jul 20. doi: 10.1007/s11030-025-11282-8.

Molecular architecture and inhibition mechanism of human ATR-ATRIP.

Sci Bull (Beijing). 2025 Jul 15;70(13):2137-2146. doi: 10.1016/j.scib.2025.05.009. Epub 2025 May 6.

Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

JCO Precis Oncol. 2022 Feb;6:e2100211. doi: 10.1200/PO.21.00211.

ATM and ATR inhibition increases radiosensitivity and cGAS-STING activation in prostate cancer.

Cytokine. 2025 Sep;193:156980. doi: 10.1016/j.cyto.2025.156980. Epub 2025 Jun 17.

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.

J Cancer Res Clin Oncol. 2023 Sep;149(11):8605-8617. doi: 10.1007/s00432-023-04804-0. Epub 2023 Apr 25.

A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase.

Biochem Pharmacol. 2025 Jul 12;241:117160. doi: 10.1016/j.bcp.2025.117160.

ATR-SEIRAS for Single-Atom Electrocatalysis.

Acc Chem Res. 2025 Jul 15;58(14):2282-2295. doi: 10.1021/acs.accounts.5c00303. Epub 2025 Jun 24.

Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.

Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.

本文引用的文献

Targeting ATR in patients with cancer.

Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20.

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.

Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5.

First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28.

ATR is essential for preservation of cell mechanics and nuclear integrity during interstitial migration.

Nat Commun. 2020 Sep 24;11(1):4828. doi: 10.1038/s41467-020-18580-9.

Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.

Cancer Res. 2020 Jun 1;80(11):2094-2100. doi: 10.1158/0008-5472.CAN-19-3126. Epub 2020 Mar 3.

A decade of clinical development of PARP inhibitors in perspective.

Ann Oncol. 2019 Sep 1;30(9):1437-1447. doi: 10.1093/annonc/mdz192.

State-of-the-art strategies for targeting the DNA damage response in cancer.

Nat Rev Clin Oncol. 2019 Feb;16(2):81-104. doi: 10.1038/s41571-018-0114-z.

Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi: 10.1016/j.stem.2017.07.010. Epub 2017 Aug 10.

ATR: an essential regulator of genome integrity.

Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27. doi: 10.1038/nrm2450. Epub 2008 Jul 2.

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Unlocking the therapeutic potential of ATR inhibitors: Advances, challenges, and opportunities in cancer therapy.

作者信息

机构信息

出版信息

相似文献

本文引用的文献